September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology Amsterdam, the Netherlands – At the American Society [...]
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid, durable, and consistent biochemical control and reduced symptom burden Launch of lead product PALSONIFY [...]
TEL AVIV, Israel, Sept. 25, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on [...]
TEL AVIV, Israel, Sept. 25, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website. Q3 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document [...]
September 25, 2025 Philips’ ambulatory and diagnostic solutions and services are now available to 3.4 million Optum policyholders for enhanced outpatient cardiac monitoring Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of [...]
TOKYO, Sept. 24, 2025 (Korea Bizwire) – Healthcare must be recognized as the world’s most strategic investment in security, prosperity, and resilience—not as a financial burden—declared H.E. Dr. Majid Alfayyadh, Adviser at the Saudi Royal Court and Chief Executive Officer of King Faisal Specialist Hospital and Research Centre (KFSHRC), in his keynote at the C3 [...]
Research Triangle Park, N.C., Sept. 22, 2025 (Korea Bizwire) – AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment of moderate-stage Parkinson’s disease in the REGENERATE-PD trial Sites in Poland and the United Kingdom have started randomizing participants, with sites in Germany actively screening and following shortly [...]
MANILA, Philippines, Sept. 22, 2025 (Korea Bizwire) – The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) today condemned the World Health Organisation’s Framework Convention on Tobacco Control (WHO FCTC) for erecting deliberate barriers to prevent public participation in the upcoming Conference of the Parties (COP11) scheduled for November in Geneva. Executive Coordinator Nancy [...]
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tablets Patients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatment Almost all (>96%) patients relayed that AUSTEDO XR was easy to take PARSIPPANY, N.J. and TEL AVIV, Israel, [...]
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-’749) and its long-term systemic safety profile was consistent with other olanzapine formulations1 Additional new data comparing initiation of UZEDY® (risperidone) versus Invega Sustenna® (paliperidone palmitate) in hospitalized patients found that UZEDY was associated with [...]